131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma

Table 1 Baseline characteristics

Characteristics	Test group (n = 95)	Control group (n = 90)	Statistical analysis
Age (yr)	50.2 (22-80)	51.4 (12-87)	NS
Sex (M/F)	83/12	76/14	NS
Child–Pugh classification			NS
Child class A	91	88
Child class B	4	2
BCLC stage			NS
C	95	90
Size of main tumors
≥ 5 cm	80	81	NS
< 5 cm	15	9	NS
Tumor/liver volume ratio
0%–50%	10	13	NS
≥ 50%	85	77	NS
Hepatitis B/C	70	76	NS
KPS	75.16 ± 7.42	73.89 ± 11.39	NS

BCLC: Barcelona clinic liver cancer; KPS: Karnofsky performance status; NS: Not significant.

Table 2 Clinical symptoms immediately after treatment n (%)

Group	Fever1	Gastrointestinal1 symptoms	Pain1	Sudden death
Test group	90 (94.74)	74 (77.89)	93 (97.89)	0
Control group	28 (31.11)	16 (17.78)	19 (21.11)	1 (1.11)

¹P < 0.001.

Table 3 Changes in blood cells and liver function before and 1 mo after treatment

Group	Test group	Control group	P value
Leukocytes	–1.25 ± 1.79	2.04 ± 11.51	0.0270
Platelets	–36.69 ± 49.62	12.74 ± 52.59	< 0.001
TB	1.7	0.95	0.860
Alb	–0.86 ± 6.89	–1.30 ± 5.36	0.6708
AST	5	7.5	0.631
ALT	–1	0	0.5137
HGB	–5.86 ± 16.42	–7.98 ± 20.26	0.515
KPS			< 0.001
Mass-associated pain			0.014

Total bilirubin (TB), Aspertate aminotransferase (AST), Glutamic-pyruvic transaminase (ALT), Karnofsky and pain (Wilcoxon rank sum test); others (t test). Alb: Albumin; HGB: Hemoglobin; KPS: Karnofsky performance score.

Table 4 Therapeutic effect evaluated according to Response Evaluation Criteria in Solid Tumors at 1 mo after treatment n (%)

Group	CR	PR	SD	PD	Effective rate (CR + PR + SD)
Test group	4 (4.11)	38 (39.73)	26 (27.40)	27 (28.77)	68 (71.23)
Control group	1 (1.11)	14 (15.56)	20 (22.22)	55 (61.11)	35 (38.89)

P < 0.001. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.